Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in adults at risk of rapidly progressive autosomal dominant polycystic kidney disease
2017-004084-12Phase 2Terminated
- Sponsor
- Sanofi
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Venglustat with Placebo (2 arms). Primary endpoint: Annualized rate of change in total kidney volume. Started May 2018; status: terminated.
02
Drugs
venglustat
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2017-004084-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004084-12.